Clinical and Translational Medicine (Oct 2024)

PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification

  • Haoyu Wang,
  • Mu Xu,
  • Tong Zhang,
  • Jinkun Pan,
  • Chaopu Li,
  • Bei Pan,
  • Linpeng Zhou,
  • Yun Huang,
  • Chenzi Gao,
  • Mengping He,
  • Yao Xue,
  • Xuetao Ji,
  • Xu Zhang,
  • Ning Wang,
  • Hongwen Zhou,
  • Qian Wang,
  • John Zhong Li

DOI
https://doi.org/10.1002/ctm2.70045
Journal volume & issue
Vol. 14, no. 10
pp. n/a – n/a

Abstract

Read online

Abstract Background Liver cancer (LC) is among the deadliest cancers worldwide, with existing treatments showing limited efficacy. This study aimed to elucidate the role and underlying mechanisms of pyrroline‐5‐carboxylate reductase 1 (PYCR1) as a potential therapeutic target in LC. Methods Immunohistochemistry and Western blot were used to analyse the expression of PYCR1 in LC cells and tissues. EdU assays, colony‐forming assays, scratch wound healing assays, Transwell assays, nude mouse xenograft models and nude mouse lung metastasis models were used to detect the growth and metastasis abilities of LC cells. Transcriptome sequencing was used to search for downstream target genes regulated by PYCR1, and metabolomics was used to identify the downstream metabolites regulated by PYCR1. ChIP assays were used to analyse the enrichment of H3K18 lactylation in the IRS1 promoter region. Results We found that the expression of PYCR1 was significantly increased in HCC and that this high expression was associated with poor prognosis in HCC patients. Knockout or inhibition of PYCR1 inhibited HCC cell proliferation, migration and invasion both in vivo and in vitro. In addition, we revealed that knocking out or inhibiting PYCR1 could inhibit glycolysis in HCC cells and reduce H3K18 lactylation of the IRS1 histone, thereby inhibiting IRS1 expression. Conclusions Our findings identify PYCR1 as a pivotal regulator of LC progression that influences tumour cell metabolism and gene expression. By demonstrating the potential of targeting PYCR1 to inhibit LC cell proliferation and metastasis, this study identified PYCR1 as a promising therapeutic target for LC. Highlights Pyrroline‐5‐carboxylate reductase 1 (PYCR1) promotes the proliferation and metastasis of liver cancer (LC) cells. The expression of PYCR1 in LC is regulated by DNA methylation. Knocking down or inhibiting PYCR1 inhibits glycolysis as well as the PI3K/AKT/mTOR and MAPK/ERK pathways in LC cells. PYCR1 regulates the transcriptional activity of IRS1 by affecting H3K18 lactylation in its promoter region.

Keywords